Thiocolchicoside - CAS 602-41-5
Catalog number: B0084-464811
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C27H33NO10S
Molecular Weight:
563.618
COA:
Inquire
Targets:
GABA Receptor
Description:
Thiocolchicoside is a semi-synthetic derivative of colchicine, an anti-inflammatory glycoside extracted from the flower seeds of superba gloriosa. Thiocolchicoside acts as a GABAA receptor antagonist exhibiting anti-inflammatory and analgesic activity. It is used as a muscle relaxant.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-464811 500 mg $199 In stock
B0084-464811 1 g $299 In stock
Bulk Inquiry
Brife Description:
GABAA receptor antagonist
Purity:
>98%
Appearance:
Yellow Solid
Synonyms:
N-[(7S)-3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; (S)-N-[3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; Coltramyl; Coltrax; Miorel; Miotens; Muscoril
Storage:
Store at -20°C
MSDS:
Inquire
Melting Point:
>197°C (dec.)
InChIKey:
LEQAKWQJCITZNK-AXHKHJLKSA-N
InChI:
InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
Canonical SMILES:
CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC4C(C(C(C(O4)CO)O)O)O
1.Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C;Bezin J;Smith A;Arnaud M;Salvo F;Haramburu F;Bégaud B;Pariente A;French Network of Pharmacovigilance Centres Drug Saf. 2017 Nov;40(11):1099-1107. doi: 10.1007/s40264-017-0561-y.
INTRODUCTION: ;The consequences of the withdrawal of marketing authorisation of drugs have mostly been studied considering drug prescription patterns for the therapeutic alternatives of the withdrawn drugs. The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often.;OBJECTIVE: ;The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons.;METHODS: ;This study was performed using both the French pharmacovigilance database and the Echantillon Généraliste des Bénéficiaires (a random sample of French health insurance affiliates). For dextropropoxyphene, pioglitazone and tetrazepam alternatives, the number and types of case reports were studied for both the year preceding the first official safety warning and the year following the withdrawal. Reporting rates expressed per 10,000 reimbursements (RR;Reimb;) and per 10,000 treated patients (RR;Pat;) were also compared for the two periods.;RESULTS: ;After dextropropoxyphene withdrawal, case reports and reimbursements increased for tramadol (case reports: +23%, reimbursements: +13%) and codeine (case reports: +74%, reimbursements: +47%), RR;Pat; being significantly increased for tramadol (0.
2.Safety of subcutaneous microinjections (mesotherapy) in musicians.
Navarte DA;Rosset-Llobet J Med Probl Perform Art. 2011 Jun;26(2):79-83.
OBJECTIVE: ;Determine the safety and tolerance of mesotherapy as a technique for the treatment of musculoskeletal complaints in musicians.;METHOD: ;67 patients (55.2% women) were subjected to a total of 267 mesotherapy sessions. A mesotherapy needle or normal needle was used randomly. The drugs employed were thiocolchicoside and diazepam as muscular relaxants, pentoxifylline or buflomedil as vasodilators, and piroxicam as an anti-inflammatory, as directed. A visual analogue scale was used to quantify the pain produced by the microinjections as well as the degree of immediate and midterm side effects as reported on a standard questionnaire.;RESULTS: ;A mean of 155.5 microinjections were performed per session, of which 45.6% were perceived as painful by the patient with a mean severity of 4.3 out of 10. The pain reduced to 0.5 out of 10 after 24 hours. The most sensitive areas were the levator scapulae and splenius muscles. Systemic symptoms were reported by 5.99% of the musicians after the mesotherapy sessions (muscular weakness 1.5%, rash 1.5%, drowsiness 1.1% and itching 1.1%, being the most frequent). The mean severity of these symptoms was 2.77 out of 10. In all cases the symptoms had completely disappeared after 24 hours.
3.Evaluation of the Effect of Mesotherapy in the Management of Osteoarthritis-Related Pain in a Police Working Dog Using the Canine Brief Pain Inventory.
Alves JC;Santos AM Top Companion Anim Med. 2017 Mar;32(1):41-43. doi: 10.1053/j.tcam.2017.07.002. Epub 2017 Jul 5.
CASE DESCRIPTON: ;A 9-year-old, 33.4kg (73.63Lb) male entire drug detection Labrador Retriever Dog was presented with an history of constant lameness from the right thoracic limb, aggravated with exercise and work.;CLINICAL FIDINGS: ;Clinical examination revealed mild signs of pain on the manipulation of the elbow joint, with reduced range of motion on the end feel of joint flexion and extension and crepitation. Radiographic examination of the right elbow joint revealed severe, chronic osteoarthritis, with osteophyte formation on the humeral epicondyles and articular margin of the distomedial humerus, with a narrowed joint space, and osteophytes on the proximal radius, proximomedial ulna, and anconeal process.;TREATMENT AND OUTCOME: ;A solution comprised of a combination of lidocaine, thiocolchicoside, and piroxicam was prepared and applied around the right elbow joint. The animal was rested for 3 days and normal work load was introduced over a 5-day period. The CPBI was completed by the trainer before treatment (T0), 14 days (T1), 1 (T2), 2 (T3), 3 (T4), 4 (T5), 5 (T6), and 6 (T7) months after treatment. Following the mesotherapy session, pain score results consistently declined until the 3-month evaluation moment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 133737-32-3 Pagoclone

Pagoclone
(CAS: 133737-32-3)

Pagoclone, an active (+)-enantiomer of the racemate RP 59037, is a ubtype selective partial agonist at GABAA receptor and used for the treatment of panic and an...

CAS 54-95-5 Cardiazole

Cardiazole
(CAS: 54-95-5)

Cardiazole is a GABA(A) receptor antagonist, causes alterations in excitatory and inhibitory neurotransmitter systems.

CAS 485-49-4 (+)-Bicuculline

(+)-Bicuculline
(CAS: 485-49-4)

(+)-Bicuculline is a competitive antagonist of GABAA receptors with IC50 of 2 μM, also blocks Ca(2+)-activated potassium channels.

CAS 164025-44-9 PZ-II-029

PZ-II-029
(CAS: 164025-44-9)

PZ-II-029,a pyrazoloquinolinone, was reported as the first postitive modulator of GABAA α6β3γ2 subtype functionally selective ligands to date.

CAS 39069-52-8 GS 39783

GS 39783
(CAS: 39069-52-8)

GS 39783 is an allosteric positive modulator of GABAB receptors, decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces...

CAS 783331-24-8 MRK 016

MRK 016
(CAS: 783331-24-8)

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...

CAS 123690-79-9 CGP 35348

CGP 35348
(CAS: 123690-79-9)

CGP 35348 is a selective and brain penetrant GABAB receptor antagonist (IC50 = 34 μM as measured in rat cortical membranes) with higher affinity for postsynapti...

CAS 128201-89-8 N-ArachidonylGABA

N-ArachidonylGABA
(CAS: 128201-89-8)

N-ArachidonylGABA is first isolated from bovine brain. It was also found to inhibit normal responses to pain in vivo, but has not been fully characterized to da...

CAS 73604-30-5 (-)-Bicuculline methobromide

(-)-Bicuculline methobromide
(CAS: 73604-30-5)

(-)-Bicuculline methobromide is the methobromide salt of (+)-bicuculline, which is a potent antagonist of GABAA receptors.

CAS 123557-91-5 rac BHFF

rac BHFF
(CAS: 123557-91-5)

BHFF is a positive allosteric modulator of GABAB receptor that increases the potency and efficacy of GABA. BHFF displays anxiolytic activity in vivo.

CAS 1236105-75-1 PHP 501 trifluoroacetate

PHP 501 trifluoroacetate
(CAS: 1236105-75-1)

PHP 501 trifluoroacetate is potent GABAA antagonist (Ki = 0.0028 μM at rat GABAA receptors; IC50 = 0.024 μM at human α1β2γ2 GABAA-expressing tsA201 cells), with...

CAS 286456-42-6 L-838,417

L-838,417
(CAS: 286456-42-6)

L-838,417 is a subtype-selective GABAA receptor partial agonist. It selectively binds to α2, α3 and α5 subunits with Ki values of 0.67, 0.67 and 2.25 nM respect...

CAS 205881-86-3 SL 651498

SL 651498
(CAS: 205881-86-3)

SL 651498 is a GABAA agonist selectively for subtype α2, and has the potential for the treatment of anxiety.

CAS 62666-20-0 Progabide

Progabide
(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

CAS 78755-81-4 Flumazenil

Flumazenil
(CAS: 78755-81-4)

Flumazenil is a GABAA receptor antagonist and the only GABAA receptor antagonist on the market today.

CAS 184845-18-9 NNC 05-2090 hydrochloride

NNC 05-2090 hydrochloride
(CAS: 184845-18-9)

NNC052090 is a GABA uptake inhibitor that displays selectivity for BGT-1 (mGAT-2) transporters.

CAS 840486-93-3 adipiplon

adipiplon
(CAS: 840486-93-3)

Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able ...

CAS 117857-45-1 Loreclezole hydrochloride

Loreclezole hydrochloride
(CAS: 117857-45-1)

Loreclezole hydrochloride is a subtype-selective GABAA receptor modulator. It acts as a positive allosteric modulator of β2 or β3-subunit containing receptors.

CAS 123691-14-5 CGP 46381

CGP 46381
(CAS: 123691-14-5)

CGP 46381 is a selective GABAB receptor antagonist (IC50 = 4.9 μM).

CAS 40709-69-1 (-)-Bicuculline methiodide

(-)-Bicuculline methiodide
(CAS: 40709-69-1)

(-)-Bicuculline methiodide is the methiodide salt of (+)-bicuculline, which is a potent antagonist of GABAA receptors.

Chemical Structure

CAS 602-41-5 Thiocolchicoside

Quick Inquiry

Verification code

Featured Items